In patients receiving perospirone (PER), correlations among the daily dose, the concentration of the PER and its metabolite ID15036 in plasma and other measures

被引：0

|

作者：

Onohara, A ^{[1
]}

Morokawa, Y ^{[1
]}

Inoue, Y ^{[1
]}

Miyake, N ^{[1
]}

Sekiguchi, G ^{[1
]}

Akimoto, T ^{[1
]}

Suzuki, H ^{[1
]}

Gen, K ^{[1
]}

Ishizeki, K ^{[1
]}

Takagi, H ^{[1
]}

Kamimura, M ^{[1
]}

Yamaguchi, N ^{[1
]}

Tanaka, A ^{[1
]}

Aoba, A ^{[1
]}

机构：

[1] St Marianna Univ, Sch Med, Kawasaki, Kanagawa, Japan

来源：

INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY | 2004年 / 7卷

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

引用

收藏

页码：S253 / S254

页数：2

相关论文

共 4 条

[1] Correlations among the perospirone (PER) daily dose, the plasma concentrations of the PER and its active metabolite ID15036, the plasma anti-D2 and anti-5-HT2A activity
Miyake, N
Morokawa, Y
Sekiguchi, G
Akimoto, T
Suzuki, H
Gen, K
Ishizeki, K
Kamimura, M
Takagi, H
Tanaka, A
Aoba, A
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2004, 7 : S421 - S421
[2] Correlations among extra pyramidal symptoms, the perospirone daily dose, the plasma concentrations of perospircine and ID15036, the plasma anti-D2 and anti-5-HT2A activity and anti-5-HT2A/D2 ratio
Miyake, N
Morokawa, Y
Sekiguchi, G
Akimoto, T
Suzuki, H
Gen, K
Kamimura, M
Takagi, H
Tanaka, A
Aoba, A
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2005, 20 (03) : A1 - A1
[3] Relationships among daily dose of perospirone, concentrations of unchanged perospirone and active metabolite ID15036, anti-D2 activity, anti-5-HT2A activity and anti-5-HT2A activity/anti-D2 activity (S/D) ratio in plasma
Miyake, N
Morokawa, Y
Sekiguchi, G
Akimoto, T
Suzuki, H
Gen, K
Ishizeki, K
Kamimura, M
Takagi, H
Tanaka, A
Aoba, A
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2004, 19 (03) : 181 - 181
[4] Relationship between daily dose of imatinib per square meter and its plasma concentration in patients with chronic-phase chronic myeloid leukemia (CML)
Horikoshi, Akira
Takei, Kazuhiro
Sawada, Shigemasa
LEUKEMIA RESEARCH, 2007, 31 (04) : 574 - 575